17 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jul 2035. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jul 2035
Next term end
15
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Aug 2035 · High confidence
Also notable
Ends Sep 2038 · High confidence
Also notable
Ends Feb 2040 · High confidence
An ANTI-CTLA4 Monoclonal Antibody or Its Antigen Binding Fragments, Pharmaceutical Compositions and Uses
US 10,449,251
The most cited patent in this portfolio, cited by 23 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2035.
ANTI-CTLA4 Antibodies
US 11,479,608
Granted 2022. Computed term ends 2038.
ANTI-VEGF-PD1 Bispecific Antibody with Novel Structure and Use Thereof
US 11,661,454
The newest of the three, granted 2023. It anchors the portfolio to 2040, later than anything else here.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 30, 2026The maintenance fee for ANTI-VEGF-PD1 Bispecific Antibody with Novel Structure and Use Thereof (US 11,661,454) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
- 1 fee due Apr 22, 2027The maintenance fee for An ANTI-CTLA4 Monoclonal Antibody or Its Antigen Binding Fragments, Pharmaceutical Compositions and Uses (US 10,449,251) comes due Apr 22, 2027. Unpaid by Oct 22, 2027, it lapses early.
Recent changes
- Nov 3Assignment recorded on 1 record: Li, Baiyong and 3 others to Akeso Biopharma, Inc. Recorded Nov 3, 2026, executed Nov 26, 2020. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76615, frame 927.
- Oct 26Assignment recorded on 1 record: Akeso Biopharma, Inc. to Akeso Biopharma Co., Ltd. Recorded Oct 26, 2026, executed Aug 6, 2020. Conveyance as recorded: Change of Name. A recorded assignment is a filed document, not a statement of current ownership. Reel 76512, frame 584.
- 2 of the patents on this record were granted since Aug 19, 2026
What they patent
The 5 largest of its 15 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| An ANTI-CTLA4 Monoclonal Antibody or Its Antigen Binding Fragments, Pharmaceutical Compositions and Uses | 3 in force | to Aug 2035 |
| ANTI-CD73-ANTI-PD-1 Bispecific Antibody and Use Thereof | 1 in force | to Mar 2044 |
| ANTI-CD73 Antibody and Use Thereof | 1 in force | to Sep 2043 |
| ANTI-CD47 Monoclonal Antibody and Use Thereof | 1 in force | to Aug 2043 |
| Anti-Tigit Antibody, and Pharmaceutical Composition and Use Thereof | 1 in force | to Jul 2043 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,291,720 | ANTI-CTLA4 Monoclonal Antibody or Its Antigen Binding Fragments, Pharmaceutical Compositions and Uses In force · High confidence | In force | High confidence | |
| US 12,447,208 | ANTI-CTLA4 Monoclonal Antibody or Its Antigen Binding Fragments, Pharmaceutical Compositions and Uses In force · High confidence | In force | High confidence | |
| US 10,449,251 | An ANTI-CTLA4 Monoclonal Antibody or Its Antigen Binding Fragments, Pharmaceutical Compositions and Uses In force · High confidence | In force | High confidence | |
| US 11,104,734 | ANTI-PD-1 Monoclonal Antibody In force · High confidence | In force | High confidence | |
| US 10,858,433 | Monoclonal Antibody Against PD-1 and Application Thereof In force · High confidence | In force | High confidence | |
| US 12,076,398 | ANTI-PD1 Monoclonal Antibody, Pharmaceutical Composition Thereof and Use Thereof In force · High confidence | In force | High confidence | |
| US 11,479,608 | ANTI-CTLA4 Antibodies In force · High confidence | In force | High confidence | |
| US 12,195,527 | ANTI-PD-1/VEGFA Bifunctional Antibody, Pharmaceutical Composition Thereof In force · Medium confidence | In force | Medium confidence | |
| US 11,680,095 | Monoclonal Antibody Against Nerve Growth Factor, and Encoding Gene and Use Thereof In force · High confidence | In force | High confidence | |
| US 11,661,454 | ANTI-VEGF-PD1 Bispecific Antibody with Novel Structure and Use Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 17: 28 applications pending · 1 application abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.